Observational studyJournal of neurology2022

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.

Kévin Bigaut et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.